A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 15
- Registration Number
- NCT06444867
- Locations
- 🇬🇧
LEO Pharma Investigational Site, London, United Kingdom
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 195
- Registration Number
- NCT06311682
- Locations
- 🇬🇧
Leo Pharma Investigational site, Sheffield, United Kingdom
A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 360
- Registration Number
- NCT06004050
- Locations
- 🇨🇳
LEO Pharma Investigational Site, Zhenjiang, China
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 402
- Registration Number
- NCT05958407
- Locations
- 🇬🇧
LEO Pharma Investigational Site, London, United Kingdom
🇪🇸LEO Investigational Site, Badalona, Barcelona, Spain
🇪🇸LEO Investigational site, Barcelona, Spain
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 250
- Registration Number
- NCT05923099
- Locations
- 🇬🇧
LEO Investigational Site, Walsall, United Kingdom
🇺🇸LEO investigational site, Indianapolis, Indiana, United States
🇺🇸LEO investigational Site, New Albany, Indiana, United States
A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 604
- Registration Number
- NCT05919082
- Locations
- 🇨🇳
LEO Pharma Investigational Site, Wenzhou, Zhejiang, China
Investigating the Safety of LEO 158968 in Healthy Volunteers
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 120
- Registration Number
- NCT05682352
- Locations
- 🇳🇱
LEO Pharma Investigational Site, Groningen, Netherlands
Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 15
- Registration Number
- NCT05486117
- Locations
- 🇩🇪
LEO Investigational Site, Hamburg, Germany
A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 13
- Registration Number
- NCT05470114
- Locations
- 🇦🇹
LEO Investigational Site, Wien, Austria
Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT05388760
- Locations
- 🇬🇧
LEO Pharma Investigational Site, Sheffield, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath